a case of villoglandular papillary adenocarcinoma of the uterine cervix diagnosed during early pregnancy followed by successful term delivery

Clicks: 191
ID: 176344
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #94 of 309 articles by views in Frontiers in pharmacology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 309 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Villoglandular papillary adenocarcinoma (VPA) is a very rare subtype of adenocarcinoma of the uterine cervix, but a well-recognized variant of cervical adenocarcinoma with a favorable prognosis and generally occurring in women of child-bearing age. Only five cases of VPA and pregnancy have been reported. Herein, we report a case of VPA diagnosed during early pregnancy and managed successfully with conservative measures; our patient delivered a healthy baby in full term. A successful pregnancy can be completed in patients with VPA without lymph-vascular invasion, when treated conservatively. This management is particularly desirable in young women to preserve reproductive capability.
Reference Key
takai2010casea Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Noriyuki Takai;Chihiro Hayashita;Satoru Nakamura;Hisashi Narahara;Hideo Matsumoto
Journal Frontiers in pharmacology
Year 2010
DOI
10.1155/2010/314547
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.